Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$43.31+0.42 (+0.98%)
Close on Nov 13, 2026Market cap $124.47MP/E –Yield –
Spruce Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Spruce Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $41.98M, up 13.8% year over year. For fiscal 2025 it was $19.52M, down 57.9% from the year before. The highest annual figure on record is $49.43M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.52M | -57.9% |
| FY2024 | Dec 31, 2024 | $46.42M | -6.1% |
| FY2023 | Dec 31, 2023 | $49.43M | +40.4% |
| FY2022 | Dec 31, 2022 | $35.20M | +14.7% |
| FY2021 | Dec 31, 2021 | $30.70M | +28.7% |
| FY2020 | Dec 31, 2020 | $23.85M | +120.5% |
| FY2019 | Dec 31, 2019 | $10.82M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.13M | +261.9% |
| Q2 FY2026 | Jun 30, 2026 | $12.16M | – |
| Q1 FY2026 | Mar 31, 2026 | $7.58M | -30.1% |
| Q4 FY2025 | Dec 31, 2025 | $4.10M | -80.9% |
| Q3 FY2025 | Sep 30, 2025 | $5.01M | -23.5% |
| Q2 FY2025 | Jun 30, 2025 | -$430.00K | -105.3% |
| Q1 FY2025 | Mar 31, 2025 | $10.84M | +5.0% |
| Q4 FY2024 | Dec 31, 2024 | $21.46M | +93.3% |
| Q3 FY2024 | Sep 30, 2024 | $6.55M | -51.4% |
| Q2 FY2024 | Jun 30, 2024 | $8.09M | -38.4% |
| Q1 FY2024 | Mar 31, 2024 | $10.32M | -11.9% |
| Q4 FY2023 | Dec 31, 2023 | $11.10M | +25.6% |
| Q3 FY2023 | Sep 30, 2023 | $13.49M | +53.5% |
| Q2 FY2023 | Jun 30, 2023 | $13.13M | +44.9% |
| Q1 FY2023 | Mar 31, 2023 | $11.71M | +37.7% |
| Q4 FY2022 | Dec 31, 2022 | $8.84M | +41.2% |
| Q3 FY2022 | Sep 30, 2022 | $8.79M | +2.1% |
| Q2 FY2022 | Jun 30, 2022 | $9.06M | -0.6% |
| Q1 FY2022 | Mar 31, 2022 | $8.51M | +26.7% |
| Q4 FY2021 | Dec 31, 2021 | $6.26M | +7.6% |
| Q3 FY2021 | Sep 30, 2021 | $8.61M | +10.8% |
| Q2 FY2021 | Jun 30, 2021 | $9.12M | +61.1% |
| Q1 FY2021 | Mar 31, 2021 | $6.71M | +45.6% |
| Q4 FY2020 | Dec 31, 2020 | $5.81M | +104.1% |
| Q3 FY2020 | Sep 30, 2020 | $7.77M | +268.7% |
| Q2 FY2020 | Jun 30, 2020 | $5.66M | – |
| Q1 FY2020 | Mar 31, 2020 | $4.61M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.85M | – |
| Q3 FY2019 | Sep 30, 2019 | $2.11M | – |
See a number that looks wrong?